Our understanding of the vitamin D receptor (VDR) and the eff ects of VDR activation has changed dramatically in recent years, with the publication of several new studies looking at selective VDR activation and eff ects on the cardio-renal syndrome (CRS). 1 Th ese advances have the potential to change the perspective of VDR activation beyond its role in mineral metabolism. Pleiotropic vitamin D eff ects have come into the focus of interest. Th e VDR Expert Centers are an independent scientifi c organization comprising a group of European academic medical centers aligned to enhance the scientifi c understanding of the VDR. Th e group is focused on increasing research collaborations, medical education, and the dissemination of knowledge in the fi eld of VDR activation. A fellows' educational program runs alongside and is intended to increase interest and build skills in clinicians and researchers entering the fi eld. Additionally, the VDR Expert Centers collaborate on research and other projects concerned with the VDR, including an annual Grand Rounds symposium, which brings together experts in the fi eld to share the latest information in this area. Th is supplement serves as a review of the data that were discussed at the inaugural Grand Rounds symposium in Amsterdam in September 2010.
A CALL FOR HOMOGENOUS NOMENCLATURE
Alongside the scientific advancements surrounding the VDR, at both preclinical and clinical levels, it is clear that the nomenclature for vitamin D and VDR activators has become more complex, though not necessarily consistent. Here, the authors of this supplement have agreed to standardize terms between the articles, so that it is clear from the outset to what molecule each author refers. For clarity in interpreting the results of each investigation, compounds are distinguished precisely; they have diff erent structures, some are inactive, some activate the VDR, and not all are detectable in the assays performed to obtain a 'vitamin D' level in our patients. Table 1 provides a summary of the vitamin D and VDR activator nomenclature used in the articles in this supplement, the fi nal column to the right containing the preferred shorthand term used here. Th roughout, this allows for a comparison of each study and a recognition that each compound may act diff erently on the same receptor.
FIGHTING VITAMIN D DEFICIENCY: WHAT ARE APPROPRIATE VITAMIN D LEVELS?
Another important issue regarding consistency in the fi eld of vitamin D is the recommended target level of 25-hydroxyvitamin D (25D), both in the general population and in chronic kidney disease (CKD) patients. Th e debate continues about how much 25D is enough or too much. Th ere is a lack of agreement between various guidelines and experts in what clinical levels of 25D are required and also how much has to be taken as supplements to achieve this. Recommendations and guidelines for optimum vitamin D levels are currently based on epidemiological and observational data and randomized controlled trials related to vitamin D intake and health outcomes are few. Vitamin D defi ciency in the general population with normal renal function causes secondary hyperparathyroidism (SHPT), bone loss, and is strongly associated with a higher risk for hypertension, proteinuria, cardiovascular (CV) lesions, and higher rates of CV mortality. 2 Th is exemplifi es the broad role that vitamin D has in several biological processes for the maintenance of general health. Nevertheless, various professional groups currently recommend diff erent levels of 25D for optimal effi cacy. For example, pulmonologists interested in cystic fi brosis, a condition where vitamin D defi ciency is common, recommended maintaining 25D levels above 35 ng/ml (87.5 nmol/l) for individuals with cystic fi brosis to avoid SHPT and bone loss. 3 recently published guidelines on vitamin D supplementation for the general population, which were much lower. 4 The IOM stated that, based on available data, almost all individuals have suffi cient 25D when their blood levels are >20 ng/ml (50 nmol/l) and that there is little additional benefi t above 30 ng/ml (75 nmol/l). In these guidelines, bone health was selected as the indicator to serve as the basis of the Dietary Reference Intake (DRIs) for Ca and vitamin D. Th ey found compelling evidence supporting the role for Ca and vitamin D in skeletal health. On the other hand, the report was inconclusive as to whether supplementing with native vitamin D or Ca is of benefi t in nonskeletal outcomes. Th ese non-skeletal outcomes are exactly what make us question whether the recent IOM recommendations are justifi ed. Limiting the appropriate vitamin D level to 20 ng/ml of 25D has initiated a vigorous scientifi c debate in the international literature. Currently, the VDR Expert Centers group, in line with the previous 2003 K/DOQI guidelines 5 and the recent Spanish recommendations for CKDmineral and bone disorder (CKD-MBD) have decided to suggest a 25D target level of >30 ng/ml. 6 Consequently, this VDR Expert Centers group essentially agrees that 25D levels of 20 ng/ml are too low for the well-being of CKD patients, and that levels of >30 ng/ml would maximize benefi t. The debate on optimum 25D levels are discussed in detail by the authors in this supplement. In their article, Pilz et al. refl ect that most CKD patients are 25D defi cient, with levels below the target of 30 ng/ml; the authors discuss the subsequent negative consequences for an increased risk of CV diseases and CV mortality. Hence, their group recommend testing for 25D levels and treating defi ciency, according to current KDIGO guidelines, and aim, in general, for a suffi cient vitamin D status with 25D levels of .30 ng/ml, the ideal target level according to many sources. 5 -9 
VITAMIN D: WHEN IS ENOUGH TOO MUCH?
However, Adriana Dusso discusses all the plausible advantages and problems of further increasing vitamin D levels, acknowledging that levels of 25D above 50 ng/ml may be detrimental to health and survival. 10 In any case, increases in plasma Ca and/or P, and probably increases in calciuria, may represent indirect evidence of undesirable high levels of 25D. Cozzolino and Bover address the issues of vitamin D levels and eff ect on mineral metabolism and bone, as well as their relation to the vasculature. Th e authors agree that the evidence points to a narrow range of 25D levels at which vascular function is optimized. 11 Th e VDR Expert Centers group acknowledges the fact that vitamin D is a potent hormone for which the risk of potential side eff ects correlates with high storage levels. However, we feel that any upper level of recommendation is even less well defi ned than the lower 25D level of >30 ng/ml. Exploring the optimal range of vitamin D levels in CKD patients, avoiding undertreatment as well as oversupplementation, is one of the main future research topics of the VDR Expert Centers group.
VITAMIN D AND CLOSELY RELATED ISSUES OF CKD-MBD
Th e review by Brandenburg et al. highlights the substantial developments that have taken place in the VDR arena in the past decade. Specifically, actions of the VDR in the heart have been explored, and the importance of vascular calcifi cations in CKD as the cause of signifi cant morbidity and mortality has been documented. Th e authors have selected what they believe are landmark publications that have improved our understanding of the mechanisms involved in the development of what they term 'vascular calcifi cations in uremia,' as well as the clinical approaches we now have to improve vascular health in CKD. Th ey touch on an article that introduced Klotho and FGF23 into the world of nephrology, and in their review Vervloet and Larsson explore in depth the fascinating discovery and mechanisms of action of these compounds. Importantly, FGF23 is a potent negative regulator of circulating P and 1,25D, so it will be interesting to see how its clinical implications in CKD as a biomarker and/or therapeutic target develop.
PERSPECTIVES
Looking to the future, randomized, controlled trials for optimizing the treatment of CKD-MBD are still needed, and more work is required to defi ne optimal target levels of Ca, P, PTH and vitamin D-as well as the new players, FGF23 and Klotho-in this population. Th ere is also the need to defi ne the potential diff erences between VDR activation with the administration of native, active, or selective forms of VDR activators. What is clear from all the articles in this supplement is that lack of VDR activation in CKD patients is a signifi cant problem that is associated with accelerated renal and CV disease progression and death. 12, 13 Th e safe correction of this deficiency without disturbing the Ca and P balance is becoming a high priority for nephrologists.
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